gp100-TCR transduced CD8 T cells

gp100-TCR transduced CD8 T cells is an experimental adoptive cell therapy (ACT) consisting of CD8+ cytotoxic T lymphocytes genetically engineered to express a T-cell receptor (TCR) specific for the gp100 (glycoprotein 100) melanoma-associated antigen. The TCR is typically designed to recognize the gp100:280–288 epitope presented by HLA-A*0201 (HLA-A2) molecules on the surface of tumor cells. This therapy involves the ex vivo expansion and viral transduction (retroviral or lentiviral) of a patient's or donor's T cells before re-infusion. Once administered, these engineered cells target and eliminate gp100-expressing melanoma cells through MHC-restricted recognition. Research has been conducted primarily in academic settings, such as the National Cancer Institute (NCI), with some constructs provided by companies like Immunocore.

Other names

gp100 TCR-Tgp-100 TCR-Tgp 100 TCR-Tgp100-specific TCR-engineered T cellsgp-100-specific TCR-engineered T cellsgp 100-specific TCR-engineered T cellsgp100-TCR CD8+ T cellsgp100-TCR transduced T cellsgp-100-TCR transduced T cellsgp 100-TCR transduced T cells